Nature Reviews Drug Discovery面向从事药物发现和开发领域的工作人员。该刊除了涵盖整个领域最高质量的综述和前瞻，每期还有新闻报道，来探讨药物发现中最热门的话题，汇总重大研究文章，及简要概述快速发展领域的最新进展，例如新药获批，专利法和新兴行业趋势。 
期刊收录研究方向：靶的发现及验证，高通量筛选，新治疗策略，药物合理设计，药物化学，天然产品，信息学，药理，毒理学，组学技术，药物输送，生物制药，疫苗，临床试验，药品监管，市场分析，战略问题，行业趋势，知识产权，药物经济学

Reviews, Perspective

Chief Editor: Peter Kirkpatrick, PhD ORCID
Peter Kirkpatrick studied for a BA at the University of Cambridge, UK, specializing in chemistry. He stayed in Cambridge for his PhD, investigating the biosynthesis and mode of action of vancomycin-group antibiotics in the group of Dudley Williams. Following post-doctoral research in this group, he joined the launch team of Nature Reviews in 2000. He joined the launch team of Nature Reviews Drug Discovery as Associate Editor in 2001, and became Chief Editor in 2004. Peter is based in London, UK.
Senior Editor: Sarah Crunkhorn, PhD ORCID
Sarah Crunkhorn studied for her BSc at the University of Sheffield where she obtained a first in pharmacology. Following her doctoral research in molecular toxicology at the University of Surrey in collaboration with GlaxoSmithKline, where she investigated mechanisms mediating xenobiotic-induced liver growth, she moved to the Joslin Diabetes Centre, Harvard Medical School, Boston, USA, for her postdoctoral research. There she carried out studies aimed to identify novel molecular mechanisms of thiazolidinedione action in humans, and explored the mechanistic role of obesity and overnutrition in modulating muscle gene expression important in the pathophysiology of insulin resistance and type 2 diabetes. She joined Nature Reviews Drug Discovery as an Associate Editor in May 2007. Sarah is based in Boston, USA.
Senior Editor: Megan Cully, PhD ORCID
Megan Cully studied biochemistry at the University of Calgary, Canada, where she was awarded the Society for Chemical Industry award as the top biochemistry student. Following her doctoral research into the mechanism of PI3K-induced tumour formation at the University of Toronto, Canada, she move to the UK to work at Cancer Research UK's London Research Institute. Under the guidance of Julian Downward, she performed a high-throughput screen and performed studies in cell culture and Drosophila melanogaster models to identify genes involved in TOR-mediated growth. She joined Nature Publishing Group in November 2012 as an Assistant Editor on Nature Reviews Cardiology and Nature Reviews Rheumatology. In January 2014, she started as an Associate Editor on Nature Reviews Drug Discovery. Megan is based in London, UK.
Senior Editor: M. Teresa Villanueva, PhD ORCID
M. Teresa Villanueva graduated with a degree in Pharmacy from the University of Granada, Spain. She obtained her PhD in Joaquín Arribas' laboratory at the Vall d'Hebrón Institute of Oncology in Barcelona, where she studied the role of the metalloproteinase TACE in breast cancer. She continued her research work as a postdoctoral fellow in the Oncological Sciences department at Mount Sinai Hospital, New York, investigating the effects of WNT signaling inhibition in breast and ovarian cancer initiation. She joined the Nature Reviews department in 2010, and after working for Nature Reviews Clinical Oncology and Nature Reviews Cancer, she joined Nature Reviews Drug Discovery as a Senior Editor in March 2017. Teresa is based in London, UK.
Associate Editor (News): Katie Kingwell
Katie Kingwell obtained a BA in physiological sciences from the University of Oxford, UK, and undertook a year of postgraduate research in the Pharmacology Department of the University of Cambridge, UK. She joined the Nature Reviews department in 2008 as Locum Copy Editor of Nature Reviews Drug Discovery, before becoming Locum Assistant Editor of that journal and Nature Reviews Neuroscience. She then worked on Nature Reviews Neurology as Associate Editor and Senior Editor, with a special interest in Alzheimer's disease and multiple sclerosis. She assumed her current role in 2014. Katie is based in London, UK.
Associate Editor: Stacey-Lynn Paiva, PhD ORCID
Stacey-Lynn Paiva obtained her BSc at Queen’s University, Canada, specializing in biochemistry. She conducted her doctoral studies at the University of Toronto, Canada, where she developed selective inhibitors of E1 activating enzymes to characterise the interplay of ubiquitin-like protein labelling systems and their mechanistic roles in physiology and disease. Following her postdoctoral work on targeted protein degradation in Craig Crews’ group at Yale University, USA, she joined Nature Reviews Drug Discovery as an Associate Editor in September 2019. Stacey-Lynn is based in London, UK.